Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Synthesis of an aryloxy oxo pyrimidinone library that displays ALK-selective inhibition.

Slavish PJ, Price JE, Jiang Q, Cui X, Morris SW, Webb TR.

Bioorg Med Chem Lett. 2011 Aug 1;21(15):4592-6. doi: 10.1016/j.bmcl.2011.05.103. Epub 2011 Jun 12.

PMID:
21708465
2.

Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.

af Gennäs GB, Mologni L, Ahmed S, Rajaratnam M, Marin O, Lindholm N, Viltadi M, Gambacorti-Passerini C, Scapozza L, Yli-Kauhaluoma J.

ChemMedChem. 2011 Sep 5;6(9):1680-92. doi: 10.1002/cmdc.201100168. Epub 2011 Jun 30.

PMID:
21721129
3.

Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.

Tripathy R, McHugh RJ, Ghose AK, Ott GR, Angeles TS, Albom MS, Huang Z, Aimone LD, Cheng M, Dorsey BD.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7261-4. doi: 10.1016/j.bmcl.2011.10.055. Epub 2011 Oct 20.

PMID:
22061645
4.

The ALK gene, an attractive target for inhibitor development.

Tartari CJ, Scapozza L, Gambacorti-Passerini C.

Curr Top Med Chem. 2011;11(11):1406-19. Review.

PMID:
21513493
5.

Design and synthesis of a novel tyrosine kinase inhibitor template.

Jake Slavish P, Jiang Q, Cui X, Morris SW, Webb TR.

Bioorg Med Chem. 2009 May 1;17(9):3308-16. doi: 10.1016/j.bmc.2009.03.046. Epub 2009 Mar 27.

6.

Virtual screening and further development of novel ALK inhibitors.

Okamoto M, Kojima H, Saito N, Okabe T, Masuda Y, Furuya T, Nagano T.

Bioorg Med Chem. 2011 May 15;19(10):3086-95. doi: 10.1016/j.bmc.2011.04.008. Epub 2011 Apr 7.

PMID:
21515061
7.

Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.

Liu Z, Yue X, Song Z, Peng X, Guo J, Ji Y, Cheng Z, Ding J, Ai J, Geng M, Zhang A.

Eur J Med Chem. 2014 Oct 30;86:438-48. doi: 10.1016/j.ejmech.2014.09.003. Epub 2014 Sep 4.

PMID:
25200979
8.

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).

Kinoshita K, Asoh K, Furuichi N, Ito T, Kawada H, Hara S, Ohwada J, Miyagi T, Kobayashi T, Takanashi K, Tsukaguchi T, Sakamoto H, Tsukuda T, Oikawa N.

Bioorg Med Chem. 2012 Feb 1;20(3):1271-80. doi: 10.1016/j.bmc.2011.12.021. Epub 2011 Dec 22.

PMID:
22225917
9.

Anaplastic lymphoma kinase in human cancer.

Schonherr C, Hallberg B, Palmer R.

Crit Rev Oncog. 2012;17(2):123-43. Review.

PMID:
22471704
10.

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.

Milkiewicz KL, Weinberg LR, Albom MS, Angeles TS, Cheng M, Ghose AK, Roemmele RC, Theroff JP, Underiner TL, Zificsak CA, Dorsey BD.

Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. doi: 10.1016/j.bmc.2010.04.087. Epub 2010 Apr 29.

PMID:
20483621
11.

Aminopyrimidinone cdc7 kinase inhibitors.

Woods KW, Lai C, Miyashiro JM, Tong Y, Florjancic AS, Han EK, Soni N, Shi Y, Lasko L, Leverson JD, Johnson EF, Shoemaker AR, Penning TD.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):1940-3. doi: 10.1016/j.bmcl.2012.01.041. Epub 2012 Jan 25.

PMID:
22326396
12.

Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.

Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG.

J Med Chem. 2008 Mar 27;51(6):1637-48. doi: 10.1021/jm701095m. Epub 2008 Feb 16.

PMID:
18278858
13.

Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.

Akritopoulou-Zanze I, Albert DH, Bousquet PF, Cunha GA, Harris CM, Moskey M, Dinges J, Stewart KD, Sowin TJ.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3136-40. Epub 2007 Mar 15.

PMID:
17391959
14.

4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.

Puig de la Bellacasa R, Roué G, Balsas P, Pérez-Galán P, Teixidó J, Colomer D, Borrell JI.

Eur J Med Chem. 2014 Oct 30;86:664-75. doi: 10.1016/j.ejmech.2014.09.018. Epub 2014 Sep 6.

PMID:
25222877
15.

Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.

Gracias V, Ji Z, Akritopoulou-Zanze I, Abad-Zapatero C, Huth JR, Song D, Hajduk PJ, Johnson EF, Glaser KB, Marcotte PA, Pease L, Soni NB, Stewart KD, Davidsen SK, Michaelides MR, Djuric SW.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2691-5. doi: 10.1016/j.bmcl.2008.03.021. Epub 2008 Mar 10.

PMID:
18362070
16.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu VL, Saffran DC, Xu M, Drew A, Merkel P, Szilvassy S, Brake RL.

J Med Chem. 2012 Jul 26;55(14):6523-40. doi: 10.1021/jm3005866. Epub 2012 Jul 10.

PMID:
22734674
17.

Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.

Xie HZ, Lan H, Pan YL, Zou J, Wang ZR, Li LL, Huang Q, Zhang H, Yang SY.

Chem Biol Drug Des. 2013 Feb;81(2):175-84. doi: 10.1111/cbdd.12084. Epub 2012 Nov 27.

PMID:
23107363
18.

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM.

J Med Chem. 1998 Aug 13;41(17):3276-92.

PMID:
9703473
19.

The design, synthesis, and biological evaluation of PIM kinase inhibitors.

Tsuhako AL, Brown DS, Koltun ES, Aay N, Arcalas A, Chan V, Du H, Engst S, Franzini M, Galan A, Huang P, Johnston S, Kane B, Kim MH, Laird AD, Lin R, Mock L, Ngan I, Pack M, Stott G, Stout TJ, Yu P, Zaharia C, Zhang W, Zhou P, Nuss JM, Kearney PC, Xu W.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3732-8. doi: 10.1016/j.bmcl.2012.04.025. Epub 2012 Apr 11.

PMID:
22542012
20.

Targeting anaplastic lymphoma kinase in lung cancer.

Shaw AT, Solomon B.

Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2. Review.

Supplemental Content

Support Center